GlassScriptPhysician profile
Erica L Ingram
NPI 1306117692
$5,563.77
in general payments reported to CMS, 2019-2025
26 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $816 · 2022: $1,142 · 2023: $1,610 · 2024: $1,347 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.33 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $716.06 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $586.51 | 2021-2025 | Caplyta |
| Lundbeck LLC | $443.83 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $423.51 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $343.00 | 2021-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $296.90 | 2021-2025 | Trintellix |
| Alkermes, INC. | $284.33 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $265.36 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $256.73 | 2022-2024 | Jornay Pm |
| Corium, LLC | $210.99 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $166.44 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $110.50 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $99.29 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $94.25 | 2023-2024 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $93.81 | 2022-2024 | Zubsolv |
| Teva Pharmaceuticals USA, INC. | $74.09 | 2021-2025 | Austedo Xr |
| Almatica Pharma LLC | $62.09 | 2023-2024 | Loreev Xr |
| Eisai INC. | $40.73 | 2021 | |
| Sunovion Pharmaceuticals INC. | $38.59 | 2021 | |
| Vertical Pharmaceuticals, LLC | $27.83 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $23.32 | 2023 | Quviviq |
| Alfasigma USA, INC. | $21.47 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.66 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $15.31 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.